- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03182725
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- University of California, San Diego
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged 18-65.
- Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE> 600pg/ml))
- Subjects with no structural heart disease
- Subject with no arrhythmias
- Subjects with norepinephrine levels greater than 600 pg/ml
- Subjects with normal CBC, Metabolic, and thyroid levels
Exclusion Criteria:
- Thyroid or adrenal disorders
- Drugs that interfere with Ivabradine (example: Cytochrome P450 drugs)
- Presentation of peripheral edema and discolored toes with peripheral autonomic neuropathy. Symptoms include: legs (reduced hair growth, cramps), toes (blue color), legs/feet (wounds, ulcers that do not heal), and muscles (numbness, heaviness)
- Subjects who have had a history of systemic illnesses (acute or chronic infectious); autoimmune/ inflammatory disease, cancer, COPD, anemia, diabetes, or psychiatric illness
- Subjects with resting heart rate< 60beats/min, atrial fibrillation, advanced AV blocks, sinus disease, and acute decompensated heart failure and severe hepatic impairment.
- Smokers or alcohol abuse
- Pregnant or breastfeeding mothers
- Woman of childbearing potential who are unwilling to use highly effective contraception during treatment and for an additional one month after discontinuing the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Patient will consume one placebo pill twice a day for one month.
|
A substance that has no therapeutic effect and will act as a control.
|
Experimental: Ivabradine
Patient will consume one dose of Ivabradine twice a day for one month.
|
Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Heart Rate
Time Frame: Baseline and one month post-treatment
|
Orthostatic heart rate monitoring will be used to gauge heart rate changes.
|
Baseline and one month post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life Via SF-36 Survey
Time Frame: Baseline and one month post-treatment
|
Medical Outcomes Study Questionnaire Short Form 36 Health Survey (SF-36) The SF-36 has 36 questions and is an indicator of overall health status and is well-validated. The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. The total score on the SF-36 ranges from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality Physical functioning Bodily pain General health perceptions Physical role functioning Emotional role functioning Social role functioning Mental health |
Baseline and one month post-treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Pam Taub, M.D., University of California, San Diego
Publications and helpful links
General Publications
- McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace. 2011 Mar;13(3):427-30. doi: 10.1093/europace/euq390. Epub 2010 Nov 9.
- Ewan V, Norton M, Newton JL. Symptom improvement in postural orthostatic tachycardia syndrome with the sinus node blocker ivabradine. Europace. 2007 Dec;9(12):1202. doi: 10.1093/europace/eum235. Epub 2007 Oct 19. No abstract available.
- Barzilai M, Jacob G. The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients. Rambam Maimonides Med J. 2015 Jul 30;6(3):e0028. doi: 10.5041/RMMJ.10213.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 170694
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postural Orthostatic Tachycardia Syndrome
-
argenxIqvia Pty LtdRecruitingPost-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia SyndromeUnited States
-
Mayo ClinicNot yet recruitingPostural Tachycardia Syndrome | Postural Orthostatic Tachycardia Syndrome | Autonomic Dysfunction | POTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Jami WarrenRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeUnited States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedPostural Tachycardia Syndrome (POTS)United States
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPostural Tachycardia Syndrome (POTS)United States
-
Lund UniversityRegion SkaneRecruitingPOTS - Postural Orthostatic Tachycardia SyndromeSweden
-
Vanderbilt University Medical CenterCompletedPostural Orthostatic Tachycardia Syndrome (POTS)United States
-
New York Medical CollegeNational Institutes of Health (NIH)CompletedOrthostatic Intolerance | Postural Orthostatic Tachycardia Syndrome (POTS) | POTSUnited States
-
University of CalgaryDysautonomia InternationalRecruiting
-
University of CalgaryCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States